SCHEMBL31401640

SCHEMBL31401640

Cc1cc(C(N)=O)cc(S(C)(=O)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.40
TPMT P51580 1/20 0.39
VNN1 O95497 1/20 0.39
MAP4K4 O95819 1/20 0.38
CA2 P00918 2/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
C1S P09871 1/20 0.38
PRSS3 P35030 1/20 0.38
PARP10 Q53GL7 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
DHODH Q02127 1/20 0.35
SLC1A3 P43003 1/20 0.35
SLC1A2 P43004 1/20 0.35
SLC1A1 P43005 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12128205 1.00 PARP1 (0.46) PARP1SMN1; SMN2TPMTVNN1MAP4K4
SCHEMBL12128201 0.83 PRSS1 (0.36) PARP1SMN1; SMN2TPMTVNN1PRSS1
SCHEMBL30525077 0.82 TPMT (0.61) SMN1; SMN2TPMTCA2ALDH1A1CA12
SCHEMBL16999094 0.82 FFAR4 (0.44) SMN1; SMN2TPMTALDH1A1
SCHEMBL20790528 0.82 TPMT (0.61) SMN1; SMN2TPMTCA2ALDH1A1CA12
SCHEMBL1172413 0.81 MAP4K4 (0.41) PARP1VNN1MAP4K4CA2PARP10
SCHEMBL25159936 0.79 PARP1 (0.44) PARP1SMN1; SMN2VNN1MAP4K4CA2
SCHEMBL23224098 0.79 ADRA1D (0.46) PARP1TPMTVNN1MAP4K4CA2
SCHEMBL501850 0.79 PARP1 (0.60) PARP1SMN1; SMN2TPMTPRSS1PRSS2
SCHEMBL12865158 0.79 PARP1 (0.60) PARP1SMN1; SMN2TPMTCA2PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed